Flexion reports Q2 EPS ($1.16), consensus ($1.23)
Reports Q2 revenue $3.8M, consensus $4.26M. "We saw strong growth in demand for ZILRETTA in the second quarter, as evidenced by a 73% increase in sales over the first quarter, and we are very pleased that the launch is on track. Based on ZILRETTA's clinical performance, rapidly growing physician awareness, broad payer coverage, the recent introduction of a product-specific Q code and the anticipated J code in January of 2019, we remain highly encouraged about the long-term potential of this important product. Furthermore, we continue to advance our robust clinical development program with the aim of expanding the label for ZILRETTA and potentially providing a new treatment option for the hundreds of thousands of patients confronting painful osteoarthritis of the hip or shoulder," said CEO Michael Clayman.